Abstract
Current antioxidant therapies targeting reactive oxygen species (ROS) are often hindered by limitations in stability, efficacy, dosage tolerance, biocompatibility, or immunogenicity. To address these challenges, we developed a therapeutic platform based on polymer microparticles composed of poly(propanediol-co-(hydroxyphenyl methylene)amino-propanediol sebacate) (PAS), fabricated via a straightforward and scalable co-solvent precipitation method. When chelated with copper(ii) ions, these microparticles (Cu-PASmp) catalytically degrade hydrogen peroxide and protect cells under oxidative stress. Both Cu-PASmp and PASmp demonstrate excellent biocompatibility and elicit no detectable immunogenic response in either M0 or M1 macrophages. Moreover, their presence appears to reduce the need for cells to express superoxide dismutase (SOD1), indicating a decrease in oxidative stress experienced by the cells. Collectively, these results position Cu-PASmp as a promising, catalytic antioxidant platform.